Medical Sector Attracts Over RMB 8.2 Billion in Q1 Funding, Multiple Firms File IPO Prospectuses

　　【Pharmaceutical Network Industry DynamicsSince 2025, the activity level of investment and financing in the healthcare sector has significantly increased. According to data statistics, in the first quarter, there were a total of 87 financing cases in China's medical device field, marking a 27.40% increase quarter-over-quarter and a 4.49% increase year-over-year. The disclosed financing scale reached 8.202 billion yuan, reflecting a 129.62% increase quarter-over-quarter and a 96.93% increase year-over-year.
 

Since May, the number of financing transactions in the medical field has continued to grow. On May 28, CareRay Medical announced the completion of a Pre-A round of financing worth tens of millions of yuan, with the investor being Luzhou Shuanggang, an industrial investment platform in Longmatan District, Luzhou City. It is reported that the funds from this round of financing will be mainly used to accelerate R&D progress, focus on breaking through technical barriers, build a talent team, construct production lines, and obtain CE certification.
 

Public information shows that Fuhan Medical is a company focused on the medicalRobotA high-tech enterprise focusing on intelligent imaging technology, the company is committed to improving medical precision and efficiency through artificial intelligence and robotics. Its core product is the intelligent blood-drawing robot. Additionally, its product range includes blood-drawing robots, ultrasound robots, 3D smart cameras, etc., with applications in medical, industrial, and other fields. It is reported that the company's first intelligent blood-drawing robot, M1pro, has obtained a type inspection report and entered the clinical trial stage. Plans are underway to obtain a Class III medical device registration certificate for the M1pro soon and to develop the M1mini (portable) blood-drawing robot.
 

News on May 27: Aisheng (Guangzhou) Biotechnology Co., Ltd. recently announced the completion of its angel round of financing. The funds will mainly be used for the clinical advancement and core technology development of small-diameter artificial blood vessels. It is reported that the company focuses on the research, production, and sales of high-end implantable medical devices. Its small-diameter artificial blood vessel product addresses clinical pain points. Currently, a Class 10,000 GMP workshop and advanced laboratories have been established in the Jiangxia District Zhongchuang Health Industry Park in Wuhan, equipped with R&D, production, and testing capabilities, while actively promoting clinical trials.
 

Fuhan Medical announced the completion of its A+ round of financing. The funds raised in this round will be mainly used to accelerate the development, registration, and market promotion of a multi-modal system for pediatric fundus imaging, an intelligent children's vision examination system, and the world’s first contact-based OCT for infants and young children. Last year, the company completed its Series A financing worth tens of millions of yuan. This A+ round of financing will further support its efforts to break the monopoly of international brands and enhance the global competitiveness of high-end ophthalmic devices produced in China.
 

In early May, Guangzhou Xinhanglu Medical Technology Company announced the completion of a 600 million RMB B-round financing jointly led by Meituan Longzhu Fund and Lilly Asia Ventures. This follows the nearly 200 million RMB A-round financing completed in August 2023, marking another successful market-driven over-subscribed financing for Xinhanglu Medical. Xinhanglu Medical is committed to developing next-generation atrial fibrillation treatment products and building a one-stop atrial fibrillation treatment solution integrating "magnetic and electric navigation + five-dimensional mapping + three-dimensional PFA ablation." This B-round financing will accelerate the research and development and registration clinical trials of Xinhanglu Medical's core electrophysiology products, further solidifying its technological and product advantages in the global electrophysiology field.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.